多西他赛联合顺铂、氟尿嘧啶一线治疗35例晚期胃癌临床观察  

Clinical observation of docetaxel combined with cisplatin plus fluorouracil as first-line therapy for advanced gastric cancer in 35 cases

作　　者：龙建林[1] 易全会 任章霞[1] 杨宁[1] 

机构地区：[1]四川省广安市人民医院肿瘤科,638000

出　　处：《重庆医学》2010年第18期2490-2491,2494,共3页Chongqing medicine

摘　　要：目的评价多西他赛联合氟尿嘧啶、顺铂一线治疗晚期胃癌的疗效（RR）、中位无进展生存时间（PFS）及安全性。方法对35例经过细胞学或组织学证实的既往未治疗的晚期胃癌患者,应用多西他赛联合氟尿嘧啶、顺铂治疗。并研究其治疗胃癌的RR、PFS及安全性。结果 1例患者因为在第1周化疗中出现消化道大出血后不愿继续化疗而退出。中位随访时间7.1个月。在能够评价疗效的34例患者中,部分缓解（PR）14例,稳定（SD）9例,进展（PD）11例,无完全缓解（CR）病例,RR为41.2%。中位PFS为5.3个月;Ⅲ~Ⅳ度中性粒细胞减少、恶心、呕吐及腹泻发生率分别54.3%、17.1%、14.3%。结论多西他赛联合氟尿嘧啶、顺铂一线治疗晚期胃癌能够提高治疗有效率,延长PFS,患者对不良反应能够耐受。Objective To evaluate the response rate,median progression-free survival and safety of docetaxel combination with cisplatin plus fluorouracil as first-line therapy for the patients with advanced gastric cancer.The primary endpoints are RR,PFS and safety.Methods 35 patients with cytological or histological confirmed previously untreated advanced gastric cancer were enrolled to achieve docetaxel plus cisplatin and fluorouracil therapy.Results One patient discontinued the therapy due to gastriointestinal hemorrahge.The median follow up time was 7.1 months.Of the 34 patients able to be evaluated on response,14 achieved PR,9 had SD and no CR gained.The median PFS was 5.3 months.Grade Ⅲ-Ⅳ of neutropenia,nausea/vomiting and diarrhea were 54.3%,14.3%,17.1%,respectively.Conclusion Docetaxel combined with cisplatin plus fluorouracil as first-line therapy for the patients with advanced gastric cancer could improve RR and PFS.The toxicity is tolerable.

关 键 词：多西他赛 一线治疗 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]